The luncheon will include a conversation about how the institutions' combined bioscience research portfolio might impact San Antonio and how it not ...
News
- Second Annual Rivard Report Medical Forum Focuses on Billion-Dollar Research Partnership
- AI isn't ready to take fund manager jobs yet
One of the Socgen Index's creators, Andrew Lapthorne, says the robot's strength is in feature recognition: picking biotech stocks that have a better ...
- PET TALK: What to know about equine osteoarthritis
Dr. Jeffrey Watkins, a professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, provides insight into equine osteoarthritis ...
- Supreme Court allows foreign investors to sue state
... the EB-5 visa program. They have reached settlements and pleaded not guilty to federal charges over a failed plan to build a biotechnology plant.
- Initial public offerings scheduled to debut next week
Vir Biotechnology - San Francisco, Calif., 7.1 million shares, priced $20-$22, managed by Goldman Sachs/JP Morgan. Proposed Nasdaq symbol VIR.